Cellectar Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cellectar Biosciences, Inc.
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.
Private Company Edition: GHO Capital will invest €975m in pharmaceutical and other opportunities in Europe, but Wellington’s $393m fund is focused on drug discovery and development. Also, Avidity raises $100m and Werewolf launches with $56m.
Starts & Stops: Check-Cap Starts US Trial; Venous Valve Study Begins; CorMatrix Looks At ‘Living’ Tricuspid Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 11 through Feb. 24, including announcements from CorMatrix Cardiovascular, Hancock Jaffe Laboratories, Toray Industries, Spectral Medical, GI Dynamics, and Check-Cap.
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
- Site Specific
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- AVAM International, Inc.
- Cellectar, Inc.
- Novelos Therapeutics, Inc.